跳至主要内容
临床试验/JPRN-UMIN000031090
JPRN-UMIN000031090已完成未知

Safety and efficacy of glecaprevir/pibrentasvir combination therapy for hepatitis C infected patients with chronic hepatitis or liver cirrhosis - glecaprevir/pibrentasvir for patients with HCV

Hokkaido University Hospital0 个研究点目标入组 300 人开始时间: 2018年1月31日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients with a past history of hypersensitivity to HCV protease inhibitors and NS5A inhibitors 2)Patients with serious liver dysfunction (Child-Pugh Class B or C) 3)Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4)Patients who have malignant tumors, including hepatoma, at the start of treatment 5)Patients on treatment with drugs listed in the contraindications for coadministration in thepackage insert (e.g., some antifungals, some antiepileptics, and human immunodeficiency virus (HIV) protease inhibitors) 6)Other patients judged to be inappropriate to participate in the study by the primary physician

研究者

相似试验